Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers

Reinvigorating the killing function of tumor-infiltrating immune cells through the targeting of regulatory molecules expressed on lymphocytes has markedly improved the prognosis of cancer patients, particularly in melanoma. While initially thought to solely strengthen adaptive T lymphocyte anti-tumo...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-07, Vol.15 (7), p.2001
Main Authors: Seo, Hobin, Verma, Amisha, Kinzel, Megan, Huang, Qiutong, Mahoney, Douglas J, Jacquelot, Nicolas
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Care and treatment
Cells
Cytokines
Cytotoxicity
Development and progression
Genotype & phenotype
Health aspects
immune cells
immune checkpoints
Immunotherapy
innate immunity
Leukemia
Lymphocytes
Medical prognosis
Melanoma
Pathogens
Prognosis
Review
Roles
T cells
Transcription factors
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reinvigorating the killing function of tumor-infiltrating immune cells through the targeting of regulatory molecules expressed on lymphocytes has markedly improved the prognosis of cancer patients, particularly in melanoma. While initially thought to solely strengthen adaptive T lymphocyte anti-tumor activity, recent investigations suggest that other immune cell subsets, particularly tissue-resident innate lymphoid cells (ILCs), may benefit from immunotherapy treatment. Here, we describe the recent findings showing immune checkpoint expression on tissue-resident and tumor-infiltrating ILCs and how their effector function is modulated by checkpoint blockade-based therapies in cancer. We discuss the therapeutic potential of ILCs beyond the classical PD-1 and CTLA-4 regulatory molecules, exploring other possibilities to manipulate ILC effector function to further impede tumor growth and quench disease progression.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15072001